Telix Pharmaceuticals (ASX:TLX) Is Up 7.1% After Resubmitting TLX101-Px NDA With FDA Fast Track Designation - Has The Bull Case Changed?

Simply Wall St.
Mar 28

In March 2026, Telix Pharmaceuticals resubmitted its New Drug Application to the FDA for TLX101-Px (Pixclara, 18F-FET), an investigational PET imaging agent for distinguishing recurrent or progressive...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10